Welcome to our dedicated page for Innate Pharma Sa news (Ticker: IPHA), a resource for investors and traders seeking the latest updates and insights on Innate Pharma Sa stock.
Innate Pharma S.A. develops clinical-stage cancer immunotherapies based on antibody engineering and target identification. Company news commonly covers its next-generation antibody therapeutics portfolio, including IPH4502, a Nectin-4 antibody-drug conjugate for solid tumors; lacutamab, an anti-KIR3DL2 antibody for cutaneous and peripheral T-cell lymphomas; monalizumab, an anti-NKG2A antibody developed with AstraZeneca for non-small cell lung cancer; and IPH5201, an anti-CD39 antibody studied in non-small cell lung cancer.
Updates also address collaborations with biopharmaceutical partners such as Sanofi and AstraZeneca, oncology conference presentations, business updates, annual meeting matters, share-count and voting-right disclosures, and annual reporting under French and U.S. public-company requirements.
Innate Pharma will host a virtual key opinion leader (KOL) discussion on February 9, 2021, at 2:00 p.m. CET / 8:00 a.m. ET, focusing on its investigational drug lacutamab for T-cell lymphomas. Presentations will be made by notable KOLs, including Pierluigi Porcu and Olivier Hermine, highlighting the drug's impact and clinical trials. The event is accessible via webcast, with registration required for dial-in details. Lacutamab targets KIR3DL2, present in a significant percentage of patients with cutaneous T-cell lymphoma, a challenging orphan disease.
Innate Pharma announced that Sanofi will advance the NKp46-based NK cell engager, IPH6101/SAR443579, into IND-enabling studies. This decision triggers a €7M milestone payment to Innate. The drug candidate has shown anti-tumor activity and promising safety data in non-human primate studies. Sanofi will handle ongoing development and commercialization. The collaboration could yield up to €400M in milestone payments and royalties for Innate. This development marks a significant step in the application of Innate’s proprietary multi-specific antibody technology in cancer therapy.
Innate Pharma SA (Euronext: IPH; Nasdaq: IPHA) announced the progression of IPH6101/SAR443579, an NKp46-based NK cell engager, into IND-enabling studies by Sanofi. This decision triggers a €7M milestone payment to Innate. The drug candidate has shown promising anti-tumor activity in pre-clinical models, including positive pharmacokinetic and safety data. Sanofi will lead future development and commercialization. This milestone is part of a collaboration allowing Innate to earn up to €400M in future development and commercial milestones.
Innate Pharma announced its participation in two upcoming virtual investor conferences. The ODDO BHF Digital Forum will take place from January 7-11, 2021, and the SternIR Virtual Corporate Access Event from January 11-14, 2021. A pre-recorded presentation will be accessible on-demand starting January 11, 2021, on their website. Innate Pharma focuses on oncology and aims to enhance treatment outcomes through innovative therapeutic antibodies. The company is recognized for its alliances with major biopharmaceutical leaders and has a robust pipeline of clinical candidates.
Innate Pharma SA (Euronext: IPH; Nasdaq: IPHA) announced it will return US and EU commercialization rights of Lumoxiti to AstraZeneca due to low product sales and strategic reassessment. The transition plan includes costs and transfer logistics, with the goal of completing the handover by 2021. The company will maintain patient and customer support during the transition but will cease regulatory activities in the EU. As of June 30, 2020, Lumoxiti's net book value stood at €45.2 million. Innate aims to refocus investments on its R&D portfolio for future growth.
Innate Pharma announced on December 11, 2020, that it will cease commercialization of Lumoxiti in the US and EU, returning these rights to AstraZeneca. The decision stems from lower-than-expected sales and the impact of the COVID-19 pandemic, prompting Innate to refocus its investments on R&D. A transition plan is set to ensure Lumoxiti's availability during the handover, with commercialization responsibilities returning to AstraZeneca in 2021. As of June 30, 2020, Lumoxiti's intangible assets were valued at €45.2 million.
Innate Pharma (Euronext: IPH, Nasdaq: IPHA) announced upcoming data presentation for its lead candidate, monalizumab, at the ESMO Immuno-oncology Virtual Congress from Dec. 9-12, 2020. The presentation will focus on a Phase 2 study of monalizumab in combination with cetuximab for patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M SCCHN) previously treated with platinum-based chemotherapy. AstraZeneca recently initiated a Phase 3 trial, INTERLINK-1, for the same combination. The agreement with AstraZeneca includes potential payments of up to $1.275 billion.
Innate Pharma SA (Euronext: IPH; Nasdaq: IPHA) announced its 2021 financial calendar. Key dates include:
- March 18, 2021: 2020 financial statements
- May 11, 2021: Q1 2021 revenue
- May 28, 2021: Annual General Shareholders Meeting
- September 15, 2021: Half-year financial statements
- November 16, 2021: Q3 2021 revenue
Reports will be released before market open CET. Innate Pharma focuses on oncology, aiming to enhance patient outcomes through innovative immune-based therapies.
Innate Pharma announced significant milestones in its latest report, including lacutamab's PRIME designation for Sézary Syndrome by the EMA, complementing its earlier FDA Fast Track designation. The initiation of the Phase 3 monalizumab study by AstraZeneca triggered a $50 million milestone payment, enhancing the company’s cash position to €163.6 million as of September 30, 2020. These achievements underscore Innate's strategic focus on developing proprietary therapies and improving patient outcomes.
Innate Pharma announced that the European Medicines Agency (EMA) has granted PRIME designation to lacutamab, its first-in-class anti-KIR3DL2 antibody, for treating patients with relapsed or refractory Sézary syndrome. This designation is based on positive efficacy and safety data from ongoing clinical trials, including the Phase 1 and Phase 2 TELLOMAK study. Lacutamab is designed to target unmet medical needs in cutaneous T-cell lymphoma patients, showing promise for those who have undergone multiple previous therapies.